
Latin America Biobanking Market Report and Forecast 2024-2032
Description
Latin America Biobanking Market Report and Forecast 2024-2032
Latin America Biobanking Market Report and Forecast 2024-2032
Latin America Biobanking Market Size
The global biobanking market was valued at USD 72.1 billion in 2023, with Latin America holding a significant market share. The market is driven by the growing demand for precision medicine and the rising focus on life science research. It is expected to grow at a CAGR of 8.60% during the forecast period of 2024-2032, with the values likely to attain USD 131.1 billion by 2032.
Latin America Biobanking Market Outlook
- Chronic diseases pose a major health challenge in Latin American countries with a substantial economic impact and mortality rates . This rising disease burden is expected to directly impact the market demand.
- One of the major Latin America biobanking market trends is the growing demand for precision medicine which stimulates the need for biobanking services. For instance, Galatea Bio, Inc., is building a biobank to accelerate drug discovery and bring precision medicine to the underserved Latin American population, leveraging advanced sequencing technologies to enrich genomic datasets.
- The growing emphasis on life science research, especially in the field of regenerative medicine and clinical studies, which are heavily dependent on high-quality biological samples is projected to boost the market share.
A biobank collects and stores biological samples along with associated health data of donors. They serve as a library for researchers and significantly reduce the time and resources needed to conduct a research study. There is a growing emphasis on life science research especially in the field of regenerative medicine and clinical studies which rely heavily on high-quality biological samples and thus are dependent on biobank facilities. This rising demand for well-maintained repositories that can store and manage these samples effectively is expected to drive the Latin America biobanking market growth. Additionally, the increased government initiatives and funding to support the establishment and expansion of biobanks are anticipated to impact the market dynamics.
The rising burden of chronic diseases is projected to impact the market dynamics. Recent data reveals that chronic diseases pose a major health challenge in Latin American countries with a substantial economic impact and mortality rates . Since biobanks act as a prerequisite in the development of new therapeutics and advanced diagnostic techniques, the market demand for these repositories is likely to augment in the forecast period. Moreover, the increasing technological advancements in biobanking practices to enhance research outcomes are anticipated to boost the Latin America biobanking market share.
One of the major market trends is the growing demand for precision medicine which stimulates the need for biobanking services to facilitate personalized approaches to disease treatment and diagnosis. For instance, the Florida-based biotechnology company Galatea Bio, Inc., is building a biobank to accelerate drug discovery and bring precision medicine to the untapped Latin American population. The company plans to have 10 million data points by 2026 and employs Illumina NovaSeq 6000 and NextSeq 2000 Systems to sequence genomes. Thus, the growth in the precision medicine sector is anticipated to elevate the market value in the coming years.
Latin America Biobanking Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Product and Service
Equipment
Consumables
Service
Software
Market Breakup by Application
Regenerative Medicine
Life Science Research
Clinical Research
Market Breakup by Sample Type
Blood Tissue
Nucleic Acids
Cell Lines
Market Breakup by End User
Academic Institutions
Pharma and Biotech Companies
Market Breakup by Country
Brazil
Argentina
Mexico
Others
Leading Players in the Latin America Biobanking Market
The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific, Inc.
- Beckman Coulter, Inc.
- Tecan Trading AG
- PHC Corporation
- Teva Pharmaceutical Industries Ltd.
- BioLife Solutions Inc.
- Merck KGaA
- Taylor-Wharton
- Panasonic Biomedical
- Custom Biogenic Systems
FAQs
- What is the Latin America biobanking market forecast outlook for 2024-2032?
- What are the major factors aiding the Latin America biobanking market demand?
- What are the major Latin America biobanking market trends?
- What is the market segmentation based on the product and services?
- What is the market breakup by sample type?
- What are the major end users of biobanking?
- What are the applications of biobanking?
- What is the market segmentation by countries?
- Who are the key players involved in the Latin America biobanking market?
Meta description
The Latin America biobanking market is poised for growth, driven by the expansion of the global market, which was valued at USD 72.1 billion in 2023 and is projected to grow at a CAGR of 6.89% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Latin America Biobanking Market Overview
- 3.1 Latin America Biobanking Market Historical Value (2017-2023)
- 3.2 Latin America Biobanking Market Forecast Value (2024-2032)
- 4 Latin America Biobanking Market Landscape*
- 4.1 Latin America Biobanking: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Latin America Biobanking: Product Landscape
- 4.2.1 Analysis by Product and Service
- 4.2.2 Analysis by Application
- 5 Latin America Biobanking Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Latin America Biobanking Market Segmentation (2017-2032)
- 6.1 Latin America Biobanking Market (2017-2032) by Product and Service
- 6.1.1 Market Overview
- 6.1.2 Equipment
- 6.1.3 Consumables
- 6.1.4 Service
- 6.1.5 Software
- 6.2 Latin America Biobanking Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Regenerative Medicine
- 6.2.3 Life Science Research
- 6.2.4 Clinical Research
- 6.3 Latin America Biobanking Market (2017-2032) by Sample Type
- 6.3.1 Market Overview
- 6.3.2 Blood Tissue
- 6.3.3 Nucleic Acids
- 6.3.4 Cell Lines
- 6.4 Latin America Biobanking Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Academic Institutions
- 6.4.3 Pharma and Biotech Companies
- 6.5 Latin America Biobanking Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 Brazil
- 6.5.3 Argentina
- 6.5.4 Mexico
- 6.5.5 Others
- 7 Brazil Biobanking Market (2017-2032)
- 7.1 Brazil Biobanking Market (2017-2032) by Product and Service
- 7.1.1 Market Overview
- 7.1.2 Equipment
- 7.1.3 Consumables
- 7.1.4 Service
- 7.1.5 Software
- 7.2 Brazil Biobanking Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Regenerative Medicine
- 7.2.3 Life Science Research
- 7.2.4 Clinical Research
- 7.3 Brazil Biobanking Market (2017-2032) by Sample Type
- 7.3.1 Market Overview
- 7.3.2 Blood Tissue
- 7.3.3 Nucleic Acids
- 7.3.4 Cell Lines
- 7.4 Brazil Biobanking Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Academic Institutions
- 7.4.3 Pharma and Biotech Companies
- 8 Argentina Biobanking Market (2017-2032)
- 8.1 Argentina Biobanking Market (2017-2032) by Product and Service
- 8.1.1 Market Overview
- 8.1.2 Equipment
- 8.1.3 Consumables
- 8.1.4 Service
- 8.1.5 Software
- 8.2 Argentina Biobanking Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Regenerative Medicine
- 8.2.3 Life Science Research
- 8.2.4 Clinical Research
- 8.3 Argentina Biobanking Market (2017-2032) by Sample Type
- 8.3.1 Market Overview
- 8.3.2 Blood Tissue
- 8.3.3 Nucleic Acids
- 8.3.4 Cell Lines
- 8.4 Argentina Biobanking Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Academic Institutions
- 8.4.3 Pharma and Biotech Companies
- 9 Mexico Biobanking Market (2017-2032)
- 9.1 Mexico Biobanking Market (2017-2032) by Product and Service
- 9.1.1 Market Overview
- 9.1.2 Equipment
- 9.1.3 Consumables
- 9.1.4 Service
- 9.1.5 Software
- 9.2 Mexico Biobanking Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Regenerative Medicine
- 9.2.3 Life Science Research
- 9.2.4 Clinical Research
- 9.3 Mexico Biobanking Market (2017-2032) by Sample Type
- 9.3.1 Market Overview
- 9.3.2 Blood Tissue
- 9.3.3 Nucleic Acids
- 9.3.4 Cell Lines
- 9.4 Mexico Biobanking Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Academic Institutions
- 9.4.3 Pharma and Biotech Companies
- 10 Regulatory Framework
- 11 Funding and Investment Analysis
- 11.1 Analysis by Funding Instances
- 11.2 Analysis by Type of Funding
- 11.3 Analysis by Funding Amount
- 11.4 Analysis by Leading Players
- 11.5 Analysis by Leading Investors
- 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
- 12.1 Analysis by Partnership Instances
- 12.2 Analysis by Type of Partnership
- 12.3 Analysis by Leading Players
- 12.4 Analysis by Geography
- 13 Supplier Landscape
- 13.1 Market Share by Top 5 Companies
- 13.2 Thermo Fisher Scientific, Inc.
- 13.2.1 Financial Analysis
- 13.2.2 Product Portfolio
- 13.2.3 Demographic Reach and Achievements
- 13.2.4 Mergers and Acquisitions
- 13.2.5 Certifications
- 13.3 Beckman Coulter, Inc.
- 13.3.1 Financial Analysis
- 13.3.2 Product Portfolio
- 13.3.3 Demographic Reach and Achievements
- 13.3.4 Mergers and Acquisitions
- 13.3.5 Certifications
- 13.4 Tecan Trading AG
- 13.4.1 Financial Analysis
- 13.4.2 Product Portfolio
- 13.4.3 Demographic Reach and Achievements
- 13.4.4 Mergers and Acquisitions
- 13.4.5 Certifications
- 13.5 PHC Corporation
- 13.5.1 Financial Analysis
- 13.5.2 Product Portfolio
- 13.5.3 Demographic Reach and Achievements
- 13.5.4 Mergers and Acquisitions
- 13.5.5 Certifications
- 13.6 Teva Pharmaceutical Industries Ltd.
- 13.6.1 Financial Analysis
- 13.6.2 Product Portfolio
- 13.6.3 Demographic Reach and Achievements
- 13.6.4 Mergers and Acquisitions
- 13.6.5 Certifications
- 13.7 BioLife Solutions Inc.
- 13.7.1 Financial Analysis
- 13.7.2 Product Portfolio
- 13.7.3 Demographic Reach and Achievements
- 13.7.4 Mergers and Acquisitions
- 13.7.5 Certifications
- 13.8 Merck KGaA
- 13.8.1 Financial Analysis
- 13.8.2 Product Portfolio
- 13.8.3 Demographic Reach and Achievements
- 13.8.4 Mergers and Acquisitions
- 13.8.5 Certifications
- 13.9 Taylor- Wharton
- 13.9.1 Financial Analysis
- 13.9.2 Product Portfolio
- 13.9.3 Demographic Reach and Achievements
- 13.9.4 Mergers and Acquisitions
- 13.9.5 Certifications
- 13.10 Panasonic biomedical
- 13.10.1 Financial Analysis
- 13.10.2 Product Portfolio
- 13.10.3 Demographic
- 13.10.4 Mergers and Acquisitions
- 13.10.5 Certifications
- 13.11 Custom biogenic systems
- 13.11.1 Financial Analysis
- 13.11.2 Product Portfolio
- 13.11.3 Demographic Reach and Achievements
- 13.11.4 Mergers and Acquisitions
- 13.11.5 Certifications
- 14 Latin America Biobanking Market – Distribution Model (Additional Insight)
- 14.1 Overview
- 14.2 Potential Distributors
- 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
- 16.1 Very Small Companies
- 16.2 Small Companies
- 16.3 Mid-Sized Companies
- 16.4 Large Companies
- 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
- 17.1 Government Funded
- 17.2 Private Insurance
- 17.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.